Search
for
Sort by
Research 31–60 of 1000+
- Clinical Manifestations of Hyperandrogenism and Ovulatory Dysfunction Are Not Associated with His1058 C/T SNP (rs1799817) Polymorphism of Insulin Receptor Gene Tyrosine Kinase Domain in Kashmiri Women with PCOS
- Synthesis, Characterisation, andIn VitroAnticancer Activity of Curcumin Analogues Bearing Pyrazole/Pyrimidine Ring Targeting EGFR Tyrosine Kinase
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- 1323 Human dermal fibroblasts and mast cell populations are altered in hidradenitis suppurativa, with epithelial-mesenchymal-transition signals ameliorated by spleen tyrosine kinase antagonism.
- Cerebral Ischemia Related to Isotretinoin; Venlafaxine-Induced Alopecia; Cognitive Dysfunction with Tolterodine; Retinal Artery Occlusion after Injection of Long-Acting Risperidone; Olanzapine-Induced Chylomicronemia Presenting as Pancreatitis; Metabolic Effects of the Atypical Antipsychotics – an Editorial; Another Drug-Induced Pancreatitis – This One Caused by a Tyrosine Kinase Inhibitor; Suicide Attempts Related to Antidepressant Medications
- 2,3,7,8‐Tetrachlorodibenzo‐<i>p</i>‐dioxin causes an increase in protein kinases growth hepatic associated with epidermal factor receptor in the plasma membrane
- Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
- The PDGF/PDGFR pathway as a drug target
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- JAK INHIBITORS IN THE PATHOGENESIS OF ALOPECIA AREATA
- JAK INHIBITORS IN THE PATHOGENESIS OF ALOPECIA AREATA
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Nilontinib induced keratosis pilaris atrophicans
- Rapid hair depigmentation in patient treated with pazopanib
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- An overview of management of drug-induced hair and nail disorders
- Hair graying and loss induced by imatinib mesylate
- Gefitinib-induced hair alterations: Figure 1
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development